Statistik Asas
| LEI | 549300S6ZD1W6BPMDY37 |
| CIK | 1564824 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Allakos Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-38582 Commission File Number ALLAKOS INC. (Exact name of registrant as specified in its charter) |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Allakos Inc. (Name of Subject Company) Allakos Inc. (Name of Persons Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 01671P100 (CUSIP Number of Class of |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ALLAKOS INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALLAKOS INC. I. The name of this corporation is Allakos Inc. (the “Corporation”). II. The registered office of the Corporation in the State of Delaware shall be 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808, and the name of the registered agent of the Corporation in the State of Delaware at such address is Co |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
AMENDED AND RESTATED BYLAWS ALLAKOS INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ALLAKOS INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Allakos Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as may be amended or modified from time to time, the “Certificate of Incorporation”). Section 1.2 Other Offices. The Corporation ma |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date earliest event reported): May 15, 2025 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ALLAKOS INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB III, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) TANG CAPIT |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38582 Allakos Inc. |
|
| April 15, 2025 |
Mutual Confidentiality Agreement Exhibit(d)(2) Mutual Confidentiality Agreement This Mutual Confidentiality Agreement (“Agreement”) is entered into as of 20 February 2025 (“Effective Date”) by and between Allakos Inc. |
|
| April 15, 2025 |
Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of ALLAKOS INC. |
|
| April 15, 2025 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ALLAKOS INC. |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Allakos Inc. (Name of Subject Company) Allakos Inc. (Name of Persons Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 01671P100 (CUSIP Number of Class o |
|
| April 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Allakos Inc. (Name of Subject Company – Issuer) Concentra Merger Sub III, Inc. (Names of Filing Persons — Offeror) Concentra Biosciences, LLC (Names of Filing Persons — Parent of Offeror) Table 1: Transaction Valuation Transaction Valuation* Fee Rate Amount of Filing Fee** Fees to Be Paid $30,612,516.66 0.00015310 $4,686.78 Fees Prev |
|
| April 15, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ALLAKOS INC. |
|
| April 15, 2025 |
Exhibit(d)(3) LIMITED GUARANTY This Limited Guaranty, dated as of April 1, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of Allakos Inc. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ALLAKOS INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB III, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) TANG CAPITAL PARTNERS, LP (N |
|
| April 15, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ALLAKOS INC. |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Allakos Inc. (Name of Subject Company) Allakos Inc. (Name of Persons Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 01671P100 (CUSIP Number of Class of Securities) Robert |
|
| April 2, 2025 |
Exhibit 99.1 Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share SAN CARLOS, Calif., April 2, 2025 (GLOBE NEWSWIRE) — Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merg |
|
| April 2, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF APRIL 1, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB III, INC. AND ALLAKOS INC. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 SECTION 1.01 Definitions 2 SECTION 1.02 Interpretation and Rules of Construction 12 ARTICLE II THE OFFER 13 SECTION 2.01 The Offer 13 SECTION 2.02 Company Actions 16 ARTICLE III THE MERGER 18 SECTION 3.01 |
|
| April 2, 2025 |
Exhibit 99.1 Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share SAN CARLOS, Calif., April 2, 2025 (GLOBE NEWSWIRE) — Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merg |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date earliest event reported): April 1, 2025 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| March 13, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 12, 2025 |
Insider Trading Policy of the Registrant. Exhibit 19.1 ALLAKOS INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities (Adopted and approved June 19, 2018 and effective as of the Company’s initial public offering. Last updated March 16, 2023.) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider |
|
| March 12, 2025 |
Exhibit 10.11d AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of November 15, 2024, by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ALLAKOS INC., a Delaware corporation (“Tenant”), with reference to t |
|
| March 12, 2025 |
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the f |
|
| March 12, 2025 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Allakos Inc. (the “Company”, “our”, “us”, or “we”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, par value $0.001 per share. The Company’s common stock is listed on Th |
|
| March 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38582 Allakos Inc. (E |
|
| February 3, 2025 |
Schedule A Transactions during the past 60 days EX-2 3 ex2.htm EXHIBIT 2 EXHIBIT 2 Schedule A Transactions during the past 60 days Transaction Date Nature of Transaction Quantity Weighted Average Price Per Share* Price Range Min Max 1/27/2025 Purchase 1,621,448 $0.31 $0.28 $0.62 1/27/2025 Purchase 2,000,000 $0.26 $0.25 $0.26 1/27/2025 Purchase 2,000,000 $0.28 $0.23 $0.30 1/28/2025 Purchase 728,694 $0.25 $0.25 $0.26 1/28/2025 Purchase 38,903 $0. |
|
| February 3, 2025 |
EX-1 2 ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to t |
|
| January 27, 2025 |
Exhibit 99.1 Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring – AK006 did not demonstrate therapeutic activity in CSU – – Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives – – Management to host conference call and webcast today at 8:30 am E.T. |
|
| January 27, 2025 |
AK006 Phase 1 CSU Study Results & Business Update January 27, 2025 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the expectations of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”) regarding its financial position and guidance, including est |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 13, 2025 |
As filed with the Securities and Exchange Commission on January 13, 2025 Registration Statement No. |
|
| January 13, 2025 |
Exhibit 107 FILING FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) ALLAKOS INC. |
|
| November 18, 2024 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| November 6, 2024 |
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results SAN CARLOS, Calif., November 6, 2024 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 10, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 10, 2024 |
Corporate Presentation October 2024 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99. |
|
| October 10, 2024 |
Exhibit 99.1 Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers – Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells – – Subcutaneous AK006 was well-tolerated with a favorable safety profile – – Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 7, 2024 |
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results SAN CARLOS, Calif., August 7, 2024 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter |
|
| August 7, 2024 |
Outside Director Compensation Policy. Exhibit 10.1 ALLAKOS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (Effective May 24, 2024) Allakos Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Direct |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| June 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 25, 2024 |
Corporate Presentation June 2024 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99. |
|
| June 25, 2024 |
Exhibit 99.1 Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile – AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occ |
|
| May 28, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 28, 2024 |
Exhibit 99.1 Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria – Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) - Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneo |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| May 9, 2024 |
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports First Quarter 2024 Financial Results SAN CARLOS, Calif., May 9, 2024 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 14, 2024 |
Exhibit 97.1 ALLAKOS INC. COMPENSATION RECOVERY POLICY (Adopted and approved on August 17, 2023 and effective as of December 1, 2023) Allakos Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to fu |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38582 Allakos Inc. (E |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 14, 2024 |
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the f |
|
| February 26, 2024 |
Exhibit 99.1 Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 – Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model – SAN CARLOS, Calif |
|
| February 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2024 |
ALLK / Allakos Inc. / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Allakos Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01671P100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2024 |
ALLK / Allakos Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 01671P100 (CUSIP Numbe |
|
| February 14, 2024 |
ALLK / Allakos Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
Exhibit 99.1 Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition – Data provide insights on the signaling pathways involved with AK006 mast cell inhibition – – AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., February 12, 2024 (GLOBE NEWSWIRE) - Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company d |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 2, 2024 |
ALLK / Allakos Inc. / RiverVest Venture Fund III, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 26, 2024 |
ALLK / Allakos Inc. / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-allk011624.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 01671P100 (CUSIP Number) January 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 26, 2024 |
ALLK / Allakos Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 18, 2024 |
SC 13G/A 1 sc13ga107422allk01182024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 p |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 01671P100 (CUSIP Number) January 16, |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 17, 2024 |
Corporate Update January 2024 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99. |
|
| January 16, 2024 |
Allakos Announces a Restructuring to Focus on Development of AK006 Exhibit 99.1 Allakos Announces a Restructuring to Focus on Development of AK006 • Existing cash to fund planned ongoing operations into mid-2026 • AK006 is being tested in a comprehensive Phase 1 clinical program, including: o ongoing single and multiple ascending dose trial in healthy volunteers o a randomized, double-blind, placebo-controlled trial in patients with CSU o a subcutaneous AK006 Pha |
|
| January 16, 2024 |
Exhibit 99.2 Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints – Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2 |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 5, 2024 |
Exhibit 107 FILING FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) ALLAKOS INC. |
|
| January 5, 2024 |
As filed with the Securities and Exchange Commission on January 5, 2024 Registration Statement No. |
|
| November 17, 2023 |
Allakos Inc. 825 Industrial Road, Suite 500 San Carlos, CA 94070 Allakos Inc. 825 Industrial Road, Suite 500 San Carlos, CA 94070 November 17, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tamika Sheppard Re: Allakos Inc. Registration Statement on Form S-3 File No. 333-275517 Acceleration Request Requested Date: November 21, 2023 Requested Time: 4:00 p.m. Ladies and Ge |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 13, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Allakos Inc. |
|
| November 13, 2023 |
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results SAN CARLOS, Calif., November 13, 2023 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 13, 2023 |
ALLK / Allakos Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment SC 13G 1 tm2328434d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class o |
|
| October 13, 2023 |
EXHIBIT 24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Seth Levy as the undersigned's true and lawful authorized representative and attorney-in-fact to execute for and on behalf of the undersigned and to file with the United States Securities and Exchange Commission and any other authority: (1) any Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act"), and the rules promulgated thereunder; and (2) any Schedule 13D or Schedule 13G, and any amendments thereto, on behalf of the undersigned in accordance with Section 13 of the 1934 Act and the rules promulgated thereunder. |
|
| October 13, 2023 |
EX-99.1 2 tm2328434d1ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Allakos Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, |
|
| August 30, 2023 |
Allakos Appoints Neil Graham to its Board of Directors Exhibit 99.1 Allakos Appoints Neil Graham to its Board of Directors SAN CARLOS, Calif., August 30, 2023 – Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 21, 2023 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ALLAKOS INC. (as amended and restated on August 17, 2023) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 9 2.6 QUORUM 9 2.7 ADJOU |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 18, 2023 |
ALLK / Allakos Inc / Alta Partners VIII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 01671P100 (CUSIP Number) Larry Randall Alta Partners 115 W Snow King Ave, Suite 101B Jackson, WY 83001 (415) 362–4022 (Name, Address and Telephone Numbe |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| August 9, 2023 |
Outside Director Compensation Policy. Exhibit 10.1 ALLAKOS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (Effective July 31, 2023) Allakos Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Direc |
|
| August 9, 2023 |
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results SAN CARLOS, Calif., August 9, 2023 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 2, 2023 |
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors Exhibit 99.1 Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors SAN CARLOS, Calif., August 2, 2023 – Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherl |
|
| June 12, 2023 |
Exhibit 99.1 Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition – AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib – – AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation – SAN CARLOS, Calif., June 12, 2023 (GLOBE NEW |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 5, 2023 |
Exhibit 99.1 Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023 SAN CARLOS, Calif., June 5, 2023 (GLOBE NEWSWIRE) - Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector c |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2023 |
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports First Quarter 2023 Financial Results SAN CARLOS, Calif., May 9, 2023 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| May 9, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of March 27, 2023, and effective as of January 1, 2022 (the “Effective Date”), by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ALLAKOS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain |
|
| May 9, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of November 15, 2022, by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and ALLAKOS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of December 4, 2019 (the “Lease”). |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 17, 2023 |
ALLK / Allakos Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 6, 2023 |
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results SAN CARLOS, Calif., March 6, 2023 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fo |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38582 Allakos Inc. (E |
|
| March 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2023 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 14, 2023 |
ALLK / Allakos Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 14, 2023 |
ALLK / Allakos Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
ALLK / Allakos Inc / Logos Global Management LP Passive Investment SC 13G/A 1 allakos13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Allakos Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01671P100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 9, 2023 |
ALLK / Allakos Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Allakos Inc. Title of Class of Securities: Common Stock CUSIP Number: 01671P100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| January 10, 2023 |
ALLK / Allakos Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ALLAKOS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 01671P100 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| January 5, 2023 |
allk-exfilingfees8.htm Exhibit 107 FILING FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) ALLAKOS INC. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggrega |
|
| January 5, 2023 |
allk-s8.htm As filed with the Securities and Exchange Commission on January 5, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 45-4798831 (State or other jurisdiction of incorporation or organizati |
|
| November 29, 2022 |
Exhibit 99.1 Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology – AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 – – AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular phagocytosis (ADCP) activity – – Allakos plans to initiate the first-in-human stu |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 10, 2022 |
Exhibit 99.1 Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting – Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells – – AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 – – Monotherap |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 7, 2022 |
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results SAN CARLOS, Calif., November 7, 2022 (GLOBE NEWSWIRE) – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third qua |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 11, 2022 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Allakos Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01671P100 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A |
|
| September 30, 2022 |
ALLK / Allakos Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 29, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 29, 2022 with respect to the Common Stock, par value $0.001 per share, of Allakos Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the pr |
|
| September 29, 2022 |
ALLK / Allakos Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 01671P100 (CUSIP Number) September 19 |
|
| September 28, 2022 |
ALLK / Allakos Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Allakos Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01671P100 (CUSIP Number) September 19, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| September 19, 2022 |
29,882,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265085 Prospectus Supplement to Prospectus dated May 31, 2022 29,882,000 Shares of Common Stock We are offering 29,882,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?ALLK.? The last reported sale price of our common stock on September |
|
| September 19, 2022 |
Exhibit 1.1 Allakos Inc. 29,882,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement September 19, 2022 Jefferies LLC Cowen and Company, LLC As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York, 10022 |
|
| September 19, 2022 |
Corporate Presentation September 2022 Exhibit 99.2 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (?Allakos,? the ?Company,? ?we? |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 19, 2022 |
Exhibit 99.1 Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock SAN CARLOS, Calif., September 19, 2022 (GLOBE NEWSWIRE) ? Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock |
|
| September 12, 2022 |
ALLK / Allakos Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 12, 2022 |
Exhibit 99.1 Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU) - Top-line Phase 2b results expected in the second half of 2023 - SAN CARLOS, Calif., September 12, 2022 (GLOBE NEWSWIRE) - Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammato |
|
| September 12, 2022 |
EX-99.A 2 d364968dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Allakos Inc. Date: September 12, 2022 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. |
|
| September 9, 2022 |
Exhibit 99.1 Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis ? Lirentelimab met histologic co?primary endpoint but missed symptomatic co?primary endpoint ? SAN CARLOS, Calif., SAN CARLOS, Calif., September 9, 2022 (GLOBE NEWSWIRE) ?? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 |
|
| September 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 5, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 5, 2022 |
Sales Agreement between the Registrant and Cowen and Company, LLC, dated August 4, 2022. EX-1.1 2 d317645dex11.htm EX-1.1 Exhibit 1.1 ALLAKOS INC. $75,000,000 SALES AGREEMENT August 4, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Allakos Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| August 4, 2022 |
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results SAN CARLOS, Calif., August 4, 2022 (GLOBE NEWSWIRE) ? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second qua |
|
| August 4, 2022 |
Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed, and has been marked with ?[***]? to indicate where omissions have been made. (1) FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED (2) FUJIFILM DIOSYNTH BIOTECHNOLOGIES TEXAS, LLC (3) FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., I |
|
| August 4, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265085 Prospectus Supplement to Prospectus dated May 31, 2022 $75,000,000 Common Stock We have entered into a Sales Agreement (?Sales Agreement?) with Cowen and Company, LLC (?Cowen?) relating to sale of shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectu |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 29, 2022 |
ALLK / Allakos Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALLAKOS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 01671P100 (CUSIP Number) JULY 21, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| July 25, 2022 |
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors Exhibit 99.1 Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) ? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 21, 2022 |
Corporate Presentation June 2022 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Exhibit 99. |
|
| June 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 31, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-265085 PROSPECTUS Allakos Inc. $250,000,000 Common Stock We may offer and sell up to $250,000,000 in the aggregate of shares of our common stock from time to time in one or more offerings. In addition, selling stockholders, as may be named in one or more prospectus supplements, may offer and sell from time to time and in one or more offerings, |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 26, 2022 |
Allakos Inc. 825 Industrial Road, Suite 500 San Carlos, California 94070 Allakos Inc. 825 Industrial Road, Suite 500 San Carlos, California 94070 May 26, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Allakos Inc. Registration Statement on Form S-3 Initially Filed May 19, 2022 File No. 333-265085 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities A |
|
| May 19, 2022 |
As filed with the Securities and Exchange Commission on May 19, 2022 As filed with the Securities and Exchange Commission on May 19, 2022 Registration No. |
|
| May 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Allakos Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carr |
|
| May 19, 2022 |
May 19, 2022 SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, N. |
|
| May 6, 2022 |
Outside Director Compensation Policy. Exhibit 10.2 ALLAKOS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (Effective April 14, 2022) Allakos Inc. (the ?Company?) believes that the granting of equity and cash compensation to its members of the Board of Directors (the ?Board,? and members of the Board, the ?Directors?) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the ?Outside Dire |
|
| May 6, 2022 |
As filed with the Securities and Exchange Commission on May 6, 2022 As filed with the Securities and Exchange Commission on May 6, 2022 Registration No. |
|
| May 6, 2022 |
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports First Quarter 2022 Financial Results REDWOOD CITY, Calif., May 6, 2022 (GLOBE NEWSWIRE) ? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarte |
|
| May 6, 2022 |
Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed, and has been marked with ?[***]? to indicate where omissions have been made. MASTER DEVELOPMENT SERVICES AGREEMENT Between SAMSUNG BIOLOGICS CO., LTD. and ALLAKOS INC. Table of Contents SECTION 1 DEFINITIONS 3 SECTION 2 RE |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| May 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2022 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Allakos Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carr |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 20, 2022 |
Separation Agreement, dated April 17, 2022, by and between Mark Asbury and Allakos Inc. Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (?Agreement?) is made by and between Mark Asbury (?Employee?) and Allakos Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS WHEREAS, Employee signed an offer letter with the Company for employment effective as ofNovember 8, 2018 (the ?Offer Letter?); |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 1, 2022 |
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Allakos Inc. (the ?Company?, ?our?, ?us?, or ?we?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): common stock, par value $0.001 per share. The Company?s common stock is listed on Th |
|
| March 1, 2022 |
Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DATED 14 February 2022 Termination wind-down and settlement Agreement among Lonza AG and Lonza Sales AG and Allakos Inc. CONTENTS CLAUSE 1. Definitions an |
|
| March 1, 2022 |
Exhibit 10.21 NOTICE OF TERMINATION February 24, 2022 From: Allakos, Inc. 975 Island Drive, Suite 201 Redwood City, California 94065 To: Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Attention: General Counsel Attention: Bradley Friedman, General Counsel Re: Notice of Termination of Sales Agreement, dated as of May 10, 2021 Ladies and Gentlemen, Reference is made to that cer |
|
| March 1, 2022 |
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results REDWOOD CITY, Calif., March 1, 2022 (GLOBE NEWSWIRE) ? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2022 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38582 Allakos Inc. (E |
|
| February 16, 2022 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 15, 2022 |
Corporate Update February 15, 2022 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; business strategy; plans and objectives for future op |
|
| February 15, 2022 |
As filed with the Securities and Exchange Commission on February 15, 2022 Registration Statement No. |
|
| February 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 15, 2022 |
Corporate Update February 15, 2022 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; business strategy; plans and objectives for future op |
|
| February 15, 2022 |
Exhibit 107 FILING FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) ALLAKOS INC. |
|
| February 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2022 |
ALLK / Allakos Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Allakos Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01671P100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2022 |
ALLK / Allakos Inc / ROCHE FINANCE LTD - SC 13G/A Passive Investment CUSIP No. 01671P100 SCHEDULE 13G/A Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Allakos Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 01671P100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Allakos Inc., which ma |
|
| February 11, 2022 |
ALLK / Allakos Inc / Capital International Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Allakos Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01671P100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 9, 2022 |
ALLK / Allakos Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Allakos Inc. Title of Class of Securities: Common Stock CUSIP Number: 01671P100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 1 |
|
| February 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 01, 2022 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 1, 2022 |
Exhibit 99.1 Allakos to Host Investor Day on February 15 ? Management will discuss lirentelimab development and Allakos pipeline ? REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) ? Allakos Inc. (the ?Company? or ?Allakos?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that it will host an |
|
| January 10, 2022 |
ALLK / Allakos Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Allakos Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01671P100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2022 |
ALLK / Allakos Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Allakos Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01671P100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| December 22, 2021 |
Exhibit 99.1 Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases ? Lirentelimab met histologic co-primary endpoints but missed symptomatic co-primary endpoints in both ENIGMA and KRYPTOS studies ? REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) ? Allakos Inc. (the ?Company? or ?Allakos |
|
| December 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 10, 2021 |
ALLK / Allakos Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Allakos Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01671P100 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 30, 2021 |
Exhibit 99.1 Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma ? Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated ? ? Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 ? ? Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022 ? ? Additional indi |
|
| November 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| November 8, 2021 |
Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results REDWOOD CITY, Calif., November 8, 2021 (GLOBE NEWSWIRE) ? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quar |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 25, 2021 |
Exhibit 99.1 Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting REDWOOD CITY, Calif., October 24, 2021 (GLOBE NEWSWIRE) - Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseas |
|
| October 25, 2021 |
Exhibit 99.2 Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation ? Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and/or eosinophil |
|
| October 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2021 Allakos Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38582 45-4798831 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 9, 2021 |
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results REDWOOD CITY, Calif., August 9, 2021 ? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the second quarter ended June 30 |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 7, 2021 |
EX-99.1 2 allk-ex9916.htm EX-99.1 Exhibit 99.1 Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002) - Results from both clinical trials expected in the fourth quarter of 2021 – - CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medic |
|
| May 26, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 24, 2021 |
Exhibit 99.1 New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms - 45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastriti |
|
| May 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38582 Allakos Inc. |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 10, 2021 |
Employment Letter between the Registrant and Harlan Baird Radford, III. EX-10.1 2 allk-ex10146.htm EX-10.1 Exhibit 10.1 Allakos Inc. April 15th, 2021 H. Baird Radford, III Dear Baird, We are pleased to confirm your offer of employment with Allakos, Inc. (“the Company”) as Chief Financial Officer. You will be a Regular, Full Time Exempt employee, reporting to Adam Tomasi, President & Chief Operating Officer or as otherwise directed. Subject to all conditions in this of |
|
| May 10, 2021 |
Sales Agreement between the Registrant and Cowen and Company, LLC, dated May 10, 2021. Exhibit 1.1 ALLAKOS INC. $400,000,000 SALES AGREEMENT May 10, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Allakos Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Ag |
|
| May 10, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233018 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Proposed maximum aggregate offering price Amount of registration fee(1) Common Stock, par value $0.001 per share $400,000,000 $43,640 (1) Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended based on the |
|
| May 10, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 10, 2021 |
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Allakos Reports First Quarter 2021 Financial Results and Provides Business Update REDWOOD CITY, Calif., May 10, 2021 ? Allakos Inc. (the ?Company?) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business upd |
|
| April 19, 2021 |
Allakos Appoints Baird Radford as Chief Financial Officer EX-99.1 2 allk-ex9916.htm EX-99.1 Exhibit 99.1 Allakos Appoints Baird Radford as Chief Financial Officer REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) - Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief F |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 14, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| March 30, 2021 |
EX-99.1 2 allk-ex9916.htm EX-99.1 Exhibit 99.1 Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) - Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disea |
|
| March 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 11, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Allakos Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01671P100 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| March 1, 2021 |
As filed with the Securities and Exchange Commission on March 1, 2021 Registration Statement No. |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2021 Allakos Inc. (Exact name of registrant as specified in its charter) Delaware 001-38582 45-4798831 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38582 Allakos Inc. (E |
|
| March 1, 2021 |
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Exhibit 99.1 Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update REDWOOD CITY, Calif., March 1, 2021 – Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year ended December 31 |
